The first stool-based CRC detection product “Cologuard,” targeting the hemoglobin, KRAS mutation, and two methylated genes (NDRG4 and BMP3), has a sensitivity of 92% and specificity of 87% for CRC (Imperiale et al., 2014); however, multiple target tests may be costly and difficult to implement. The gene discussed is KRAS; the disease is colorectal carcinoma.